Long-acting medication for the treatment of opioid dependence

This website has been developed by Camurus UK to provide information about Buvidal (buprenorphine – prolonged release solution for injection) in the United Kingdom.

Most people in the UK receiving Opioid Dependence Treatment (ODT) are prescribed daily medication that may require supervised self-administration.

Whilst this standard of care is effective for many patients, the routine of daily treatment inevitably impacts on their lives.

Buvidal is a prolonged release medication for the treatment of opioid dependence and is available as either a weekly or monthly subcutaneous injection.

Buvidal contains the active ingredient buprenorphine, which suppresses withdrawal and cravings associated with opioid dependence.

Due to its slow-release properties, patients treated with Buvidal no longer face the potentially restrictive and stigmatising routine of daily visits to a pharmacy or drug treatment service for supervised medication.

Important

Only healthcare professionals can administer Buvidal and treatment should be part of a comprehensive programme that also includes wraparound care, in the form of social and psychological support.

Information at your fingertips

Our website is designed to not only give you lots of useful information and resources about Buvidal, but also advice on how to introduce Buvidal into a drug treatment service.

It is intended for a broad audience of healthcare professionals and other relevant decision makers working in the field of drug addiction – including commissioners, prescribers, pharmacists, nursing and professional support staff.

In addition to sharing our own knowledge and expertise we have also invited HCPs and patients to share their experience of Buvidal in the hope that this real world and lived experience can help others understand both the benefits and practicalities of delivering Buvidal treatment.